Medicare launched a new program in July offering some seniors GLP-1 weight-loss drugs for $50 a month. The catch, reported by KFF Health News, is that patients with the most serious conditions are excluded from that price. For brokers advising employer clients on GLP-1 coverage design, the access gap built into the federal program is exactly the kind of structural detail that shapes the advice.
The program is called the Medicare GLP-1 Bridge. Run by the Centers for Medicare and Medicaid Services (CMS), it covers three GLP-1 medications - Wegovy, the KwikPen formulation of Zepbound, and the oral drug Foundayo - for eligible Medicare Part D enrollees at a $50 monthly copay. The demonstration runs through December 31, 2027. It operates outside the standard Part D benefit, meaning Part D plans do not need to opt in and do not carry the drug costs.
Federal law has long barred Medicare from covering drugs prescribed solely for weight loss. The Bridge works around that prohibition by running as a demonstration project, collecting utilization data to assess whether GLP-1 access reduces downstream Medicare costs. CMS confirmed that most prior authorization requests are being processed in under 12 hours.
The $50 price applies only to enrollees using GLP-1s for weight loss who do not already have a medical condition that Medicare covers GLP-1s to treat. Anyone with a diagnosis of Type 2 diabetes, moderate to severe obstructive sleep apnea, or metabolic dysfunction-associated steatohepatitis is routed back to their standard Part D plan. Under Part D, GLP-1 copays typically run $200 to $600 a month or more, according to KFF Health News.
The exclusion produces a counterintuitive outcome. Juliette Cubanski, who directs the Program on Medicare Policy at KFF, told KFF Health News that the Bridge was designed for people who cannot get GLP-1 coverage through Part D. Those who already have qualifying diagnoses are technically covered by Part D - just at a cost many cannot afford.
KFF estimated that 3.8 million Medicare Part D enrollees met Bridge eligibility criteria based on 2023 claims data, out of 9.7 million who met the clinical criteria for obesity or overweight. The gap is the 5.9 million with conditions such as diabetes or sleep apnea that route them to Part D rather than Bridge. At 25% participation among eligible enrollees over the program's 18 months, the cost to Medicare would reach approximately $3.3 billion, according to KFF. At 75% participation, that figure rises to $10 billion.
The Bridge program's access gap illustrates a design challenge that employer plan sponsors face when structuring GLP-1 coverage: the same drug can be indicated for multiple conditions, but how a plan covers it produces different outcomes depending on an employee's diagnosis.
In group plans, the relevant question is whether GLP-1 coverage is structured around diabetes only, weight loss only, or both. A 2026 survey by the International Foundation of Employee Benefit Plans (IFEBP) of nearly 300 US health plans found that 60% of employers cover GLP-1 drugs for diabetes only, up from 55% in 2025. Just 36% cover them for both diabetes and weight loss, unchanged year over year. GLP-1 drugs now account for 11.4% of annual claims among employers that cover them for weight loss, up from 6.9% in 2023.
An employee with sleep apnea or cardiovascular disease who needs a GLP-1 for that indication exists in the same coverage ambiguity on the employer side as they do in Medicare. Brokers helping clients design or review pharmacy benefits need to account for that complexity as GLP-1 indications continue to expand. The share of large employers covering GLP-1s for obesity fell from 72% in 2025 to 60% in 2026, with many tightening utilization management rather than eliminating coverage outright.
Taylor Lacy, a primary care physician at Sunflower Medical Group in Roeland Park, Kansas, told KFF Health News that the Bridge program is leaving behind patients with the greatest medical need. Many Medicare patients who do qualify for Part D GLP-1 coverage still face copays of $200 to $600 a month after completing prior authorization and step therapy requirements. "Coverage doesn't always mean affordable," she said.
That tension plays out on the employer benefits side too. Point-solution vendors for GLP-1 management are now used by 28% of employers, up from 11% in 2024, based on a National Alliance of Healthcare Purchaser Coalitions survey. Many combine prior authorization, clinical eligibility gatekeeping, and patient support in a single program - the kind of structured approach the Bridge's two-tier access design demonstrates is needed even in a government program.
If CMS, with direct control over program design, still produced a coverage structure that excludes its sickest patients from the discount, employer clients building GLP-1 policies face the same challenge at smaller scale. The employers managing GLP-1 cost pressure most effectively in 2026 are those that have moved from binary coverage or exclusion decisions toward structured access frameworks: clinical eligibility gating, step therapy, and outcomes tracking.
